How to buy Biogen stock
Learn how to easily invest in Biogen stock.
Biogen is a drug manufacturers-general business based in the US. Biogen shares (BIIB) are listed on the NASDAQ and all prices are listed in US Dollars. Biogen employs 8,725 staff and has a trailing 12-month revenue of around $10 billion.
How to buy Biogen stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – BIIB. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 in stock when you fund a new account within 30 days
- Easy to use platform with $0 stock trading & no annual fees
- Social trading allows you to copy popular portfolios
- FINDER EXCLUSIVE: Guaranteed $15 bonus when you sign up and deposit $100
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+
Biogen stock price (NASDAQ: BIIB)Use our graph to track the performance of BIIB stocks over time.
Biogen shares at a glance
|Latest market close||$257.68|
|52-week range||$194.63 - $319.76|
|50-day moving average||$266.74|
|200-day moving average||$281.70|
|Wall St. target price||$333.66|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$18.23|
Buy Biogen stock from these online trading platformsCompare special offers, low fees and a wide range of investment options among top trading platforms.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Is it a good time to buy Biogen stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Biogen price performance over time
|1 week (2023-09-15)||1.13%|
|1 month (2023-08-24)||-1.81%|
|3 months (2023-06-23)||-9.43%|
|6 months (2023-03-24)||-4.57%|
|1 year (2022-09-23)||30.29%|
|2 years (2021-09-20)||-13.67%|
|3 years (2020-09-24)||270.04|
|5 years (2018-09-24)||347.02|
Is Biogen stock undervalued or overvalued?
Valuing Biogen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Biogen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Biogen's P/E ratio
Biogen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 14x. In other words, Biogen shares trade at around 14x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Biogen's PEG ratio
Biogen's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 36.1919. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Biogen's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Biogen's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.1 billion.
The EBITDA is a measure of a Biogen's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$10 billion|
|Operating margin TTM||26.24%|
|Gross profit TTM||$7.9 billion|
|Return on assets TTM||6.51%|
|Return on equity TTM||20.25%|
|Market Capitalization||$37.5 billion|
TTM: trailing 12 months
Biogen share dividends
We're not expecting Biogen to pay a dividend over the next 12 months.
Have Biogen's shares ever split?
Biogen's shares were split on a 3:1 basis on 17 January 2001. So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Biogen shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for Biogen shares which in turn could have impacted Biogen's share price.
Biogen share price volatility
Over the last 12 months, Biogen's shares have ranged in value from as little as $194.63 up to $319.76. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biogen's is 0.1321. This would suggest that Biogen's shares are less volatile than average (for this exchange).
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.
Biogen in the news
GE Healthcare: why it's still waiting on its Leqembi windfall
Biogen Inc.'s (NASDAQ:BIIB) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Biogen Inc. (BIIB) Stock Moves -0.19%: What You Should Know
Frequently asked questionsWhat percentage of Biogen is owned by insiders or institutions?
Currently 0.679% of Biogen shares are held by insiders and 90.871% by institutions. How many people work for Biogen?
Latest data suggests 8,725 work at Biogen. When does the fiscal year end for Biogen?
Biogen's fiscal year ends in December. Where is Biogen based?
Biogen's address is: 225 Binney Street, Cambridge, MA, United States, 02142 What is Biogen's ISIN number?
Biogen's international securities identification number is: US09062X1037 What is Biogen's CUSIP number?
Biogen's Committee on Uniform Securities Identification Procedures number is: 449370105
More guides on Finder
How to buy Discord stock when it goes public
Everything we know about the Discord IPO, plus information on how to buy in.
Today’s trending Reddit stocks
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
How to buy Tottenham Acquisition I stock
Steps to owning and managing TOTA, with 24-hour and historical pricing before you buy.
How to buy TotalEnergies stock
Steps to owning and managing TOT, with 24-hour and historical pricing before you buy.
How to buy Thunder Bridge Acquisition stock
Steps to owning and managing THBR, with 24-hour and historical pricing before you buy.
How to buy Switchback Energy Acquisition Corporation stock
Steps to owning and managing SBE, with 24-hour and historical pricing before you buy.
How to buy Telefonica SA ADR stock
Steps to owning and managing TEF, with 24-hour and historical pricing before you buy.
How to buy Faraday Future stock
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
How to buy Phoenix Tree stock
Steps to owning and managing DNK, with 24-hour and historical pricing before you buy.
How to buy Innate Pharma stock
Steps to owning and managing IPHA, with 24-hour and historical pricing before you buy.
Ask an Expert